Abstract
ObjectiveWe previously reported that patients with cholesteryl ester transfer protein (CETP) deficiency (CETP-D) have a higher prevalence of atherosclerotic cardiovascular disease, in spite of increased HDL-C levels. However, characterization of HDL in CETP-D has not been well described. Therefore, we examined HDL particle number (PN) rather than HDL-C level.Approach and resultsNine patients with CETP-D and 9 normolipidemic subjects were enrolled. We performed gel permeation high-performance liquid chromatography (GP-HPLC) analysis, determined the cholesterol and triglyceride composition of all lipoprotein subclasses, and calculated the PN of each subclass, which consisted of 3 VLDL (large, medium, and small), 4 LDL (large, medium, small, and very small), and 5 HDL (very large, large, medium, small, and very small) subclasses. The PNs of large and medium LDL were significantly lower in CETP-D than that in healthy subjects (0.66- and 0.63-fold decrease, respectively; p<0.001), whereas the PN of very small LDL, which is known to be atherogenic, was significantly higher (1.36-fold increase, p = 0.016). The PNs of very large and large HDL in CETP-D were markedly higher than that in healthy subjects (19.9- and 4.5-fold increase, respectively; p<0.001), whereas the PNs of small and very small HDL, which have more potent anti-atherogenic functions, were significantly lower (0.76- and 0.61-fold decrease, respectively; p<0.001).ConclusionWe have assessed the PNs of detailed subclasses of patients with CETP-D for the first time. The PN of larger HDL was markedly increased, that of smaller HDL was decreased, and that of very small LDL was increased, suggesting that CETP-D has pro-atherogenic lipoprotein properties.
Highlights
Epidemiological studies have shown that high LDL-cholesterol (LDL-C) and low HDL-cholesterol (HDL-C) levels are positively and independently correlated with cardiovascular disease (CVD) events[1]
We have assessed the particle number (PN) of detailed subclasses of patients with cholesteryl ester transfer protein (CETP)-D for the first time
We previously reported that patients with hyperalphalipoproteinemia (HALP) caused by CETP deficiency (CETP-D), who showed similar lipid profiles to CETP inhibitor-treated patients, were not protected against CVD[9]
Summary
Epidemiological studies have shown that high LDL-cholesterol (LDL-C) and low HDL-cholesterol (HDL-C) levels are positively and independently correlated with cardiovascular disease (CVD) events[1]. Drugs that increase HDL-C levels, such as niacin[4] and most cholesteryl ester transfer protein (CETP) inhibitors, have been unable to reduce CVD events. Studies of the CETP inhibitors torcetrapib[5], dalcetrapib[6], and evacetrapib[7] were terminated because of increased mortality or no significant effects on major CVD events, these drugs increased HDL-C or even decreased LDL-C levels. We previously reported that patients with hyperalphalipoproteinemia (HALP) caused by CETP deficiency (CETP-D), who showed similar lipid profiles to CETP inhibitor-treated patients, were not protected against CVD[9]. We hypothesized that inhibition or deficiency of CETP might affect the structural alterations of lipoproteins, including lipoprotein particle distribution or lipoprotein particle numbers (PNs)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.